Lovaltech announces the release of the first clinical batch of LVT-001, its intranasal COVID-19 vaccine, manufactured by GTP Bioways CDMO –
A Pivotal Step Toward Clinical Trials
Lovaltech reaches a major milestone in the fight against COVID-19:
First Clinical Batch of LVT-001, an Innovative Intranasal Vaccine, Released by GTP Bioways CDMO
A Decisive Advance Toward Clinical Trials of a Next-Generation Vaccine
Tours, March 17, 2025. Lovaltech, a French biotechnology company at the forefront of vaccine innovation, and GTP Bioways CDMO, a leading pharmaceutical contract manufacturer, announce the release of the first clinical batch of LVT-001, a groundbreaking intranasal COVID-19 vaccine. This critical milestone paves the way for imminent clinical trials to demonstrate LVT-001’s potential superiority over current mRNA vaccines.
LVT-001: A Novel approach for enhanced protection
LVT-001 leverages recombinant protein technology, free of adjuvants, and is administered intranasally for a more patient-friendly, needle-free experience. This next-generation vaccine is designed to provide protection against infection and transmission, including emerging variants, with the ambition of delivering universal and long-lasting immunity. The GMP-compliant manufacturing of this first batch underscores Lovaltech and GTP Bioways CDMO’s ability to scale an innovative biological production process with pharmaceutical-grade precision.
A project rooted in French excellence
Labeled as a Deeptech company by Bpifrance, Lovaltech holds an exclusive global license for the LVT-001 patent, the result of an exemplary collaboration between academia and industry, involving the University of Tours, INRAE, the University of Lille, Lille University Hospital, and INSERM.
Patrick Barillot, CEO of Lovaltech, states: “This milestone demonstrates our ability to turn cutting-edge scientific advances into tangible health solutions. We are proud to be pioneering the next generation of mucosal vaccines against infectious diseases.”
Alain Sainsot, CEO of GTP Bioways CDMO, adds: “Our collaboration with Lovaltech perfectly illustrates how industrial expertise can accelerate the development of innovative therapeutic solutions.”
About Lovaltech
Lovaltech is a cutting-edge biotechnology company dedicated to developing innovative vaccines to address global health emergencies. Its vaccine platform aims to accelerate the development of new protein-based intranasal vaccines, targeting poorly covered infectious diseases and future pandemics. www.lovaltechnology.com
About GTP Bioways CDMO
GTP Bioways is a Contract Development and Manufacturing Organization (CDMO) providing comprehensive manufacturing services to support biopharmaceutical companies from preclinical trials to commercial production of their therapies.
As a member of the Olon Group, GTP Bioways benefits from strengthened strategic synergies and now offers large-scale production capabilities to support commercial manufacturing. Its expertise covers industrial process development and the production of biological molecules—using both mammalian and microbial hosts—as well as the manufacturing of bioconjugates and nanoformulated drugs. GTP Bioways stands out as one of the few CDMOs capable of mastering the entire biotherapeutics value chain, offering integrated services from cell line and strain development to aseptic filling. www.gtp-bioways.com
